Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast can

[News]

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

More... (http://www.news-medical.net/news/20111018/Positive-results-from-Roches-Phase-3-HannaH-trial-for-HER2-positive-early-breast-cancer.aspx)

[Laurel]

Wow, now that is cool! We could self-administer our Neulasta AND later on in our treatment our Herceptin!